In the article titled "The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes" [1], there was an error regarding the FRAX® tool, which should be clarified as follows: The article notes: "Even the FRAX (fractures risk assessment tool), an algorithm adopted by the WHO to assess the risk of fractures, does not seem useful in T2D patients [186]." However, the World Health Organization (WHO) did not develop, test, or endorse the FRAX tool or its recommendations [2]. The metabolic bone disease unit at the University of Sheffield that developed FRAX was a WHO Collaborating Centre from 1991 to 2010, but treatment guidelines must undergo a formal process before they can be endorsed by the WHO.
Corrigendum to "The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes"
Strollo, Rocky;Briganti, Silvia I;
2017-01-01
Abstract
In the article titled "The Alliance of Mesenchymal Stem Cells, Bone, and Diabetes" [1], there was an error regarding the FRAX® tool, which should be clarified as follows: The article notes: "Even the FRAX (fractures risk assessment tool), an algorithm adopted by the WHO to assess the risk of fractures, does not seem useful in T2D patients [186]." However, the World Health Organization (WHO) did not develop, test, or endorse the FRAX tool or its recommendations [2]. The metabolic bone disease unit at the University of Sheffield that developed FRAX was a WHO Collaborating Centre from 1991 to 2010, but treatment guidelines must undergo a formal process before they can be endorsed by the WHO.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
